In Saccharomyces cerevisiae, the repressive chromatin environment at telomeres gives rise to telomere position effect (TPE), the epigenetic silencing of telomere-proximal genes. Chromatinmodifying factors that control TPE in yeast have been extensively studied, and among these, the lifespan regulator and silencing protein Sir2 plays a pivotal role. In contrast, the factors that generate and maintain silent telomeric chromatin in human cells remain largely unknown. Here we show that the Sir2 family member SIRT6 is required for maintenance of TPE in human cells. RNAi-mediated depletion of SIRT6 abrogates silencing of both an integrated telomeric transgene and an endogenous telomere-proximal gene. Moreover, enhanced telomeric silencing in response to telomere elongation is associated with increased repressive chromatin marks, and this heterochromatic milieu is lost in SIRT6-deficient cells. Together, these findings establish a new role for SIRT6 in regulating an aging-associated epigenetic silencing process and provide new mechanistic insight into chromatin silencing at telomeres.
increased repressive chromatin environment that results from longer telomeres 9, 10 . Like their yeast counterparts, mammalian telomeres can exert silencing effects on adjacent genes [11] [12] [13] . However, aside from downstream changes such as altered histone methylation patterns and suggestions that HP1 is involved 12, 14 , the upstream factors required for telomeric gene silencing in human cells remain largely unknown.
The Sir2 family member SIRT6 is a highly substrate-specific histone deacetylase that promotes proper chromatin function in several physiologic contexts, including genome stabilization, DNA repair, and gene expression. Early work implicated SIRT6 in regulating aging-associated pathologies and lifespan in mice 15 . Subsequently, SIRT6 was shown to possess NAD + -dependent histone deacetylase activity, with specificity for lysines 9 and 56 of histone H3 (H3K9 and H3K56, respectively) [16] [17] [18] .
Since the discovery of its enzymatic activity, SIRT6 has been shown to function in several important genomic contexts. First, SIRT6 modulates telomeric chromatin in mammalian cells 16, 17 . By deacetylating H3K9 and H3K56 at telomeres during S-phase, SIRT6 is required for proper replication of telomeres. Depletion of SIRT6 from human cells results in abnormal telomere structures and stochastic replication-associated telomere sequence loss, ultimately leading to genomic instability, chromosomal end-to-end-fusions, and premature cellular senescence 11 .
In addition to its role at telomeres, SIRT6 also plays a critical role in regulating DNA repair. SIRT6 associates dynamically with chromatin flanking DNA double-strand breaks (DSBs) and is required for stabilization of the non-homologous end-joining (NHEJ) protein DNAPKcs at DSBs and for efficient repair of these breaks 19 . Recently, SIRT6 was shown to promote DNA DSB repair through several additional mechanisms, including stimulating DNA end-resection in homology-directed repair (HDR; ref 20 ) and activating the poly-ADP ribosyltransferase PARP-1 to promote NHEJ and HDR 21 .
Finally, histone deacetylation by SIRT6 is important for active transcriptional repression of gene expression networks linked to aging and metabolism 22, 23 . For example, SIRT6 functions at specific NF-κB target gene promoters to attenuate gene expression, providing an important link between SIRT6 and active gene repression 22 . More recently, SIRT6 was also shown to repress expression of genes involved in glucose and fat metabolism [23] [24] [25] [26] . However, no role for SIRT6 in the generation or maintenance of silent chromatin domainsat telomeres or elsewhere-has yet been described.
Here we uncover a novel role for SIRT6 in maintaining TPE in human cells. We show that SIRT6 dynamically regulates the silencing of a telomere-proximal transgene and that depletion of SIRT6 leads to loss of TPE-associated heterochromatic marks. In addition, we show that SIRT6 is required for the repression of an endogenous telomere-proximal gene. These findings indicate that SIRT6 is important for maintaining a proper telomeric chromatin structure that is required for silencing of nearby genes.
Results

Silencing of a telomere-proximal reporter gene requires SIRT6
The growing evidence that proper chromatin silencing is important for mammalian aging and cancer, together with the site-specific histone deacetylation activity and telomeric functions of SIRT6, led us to ask whether SIRT6 modulates TPE in human cells. To address this question, we used a previously established luciferase-based system that recapitulates important features of TPE in yeast. In this system, a luciferase reporter gene is stably integrated into the genome of human cervical cancer (HeLa) cells at either a telomeric position or an internal chromosomal position (Figure 1a, ref 11 ). As previously shown, overexpression of human telomerase reverse transcriptase (hTERT) in these cells-and concomitant lengthening of bulk telomeres-dramatically reduced telomeric luciferase expression (Fig. 1b , and see ref 11 ), indicating that the strength of silencing is proportional to telomere length, as has been observed in yeast 7, 8 . These data confirm that our system recapitulates important features of the Sir2-dependent silencing of telomere-proximal genes in yeast.
We next used this system to ask whether SIRT6 is required for TPE in human cells. siRNAmediated depletion of SIRT6 significantly increased telomeric luciferase expression, and this effect was particularly strong in cells with long telomeres (Fig. 2a) . In contrast, SIRT6 depletion did not affect the expression of an internally integrated luciferase gene, highlighting the specificity of the de-repression (Fig. 2a) . This telomere-specific loss of silencing was also observed in a second set of cell lines in which the luciferase genes were integrated at distinct telomeric and internal sites (Fig. 2b) ; we note that the differential effect of SIRT6 depletion on telomeric luciferase expression in the two cell lines is consistent with observed differences in the repressive capacity of different telomeres in yeast 27 . A second independent SIRT6-directed siRNA revealed a dose-dependent effect of SIRT6 depletion on loss of telomeric silencing (Fig. 2c,e) . In contrast, depletion of SIRT1-another nuclear Sir2 family member recently linked to telomere function 28 -did not trigger telomere-specific derepression but instead had a rather subtle effect on both telomeric and non-telomeric luciferase expression (Fig. 2d) . Together, these observations reveal that SIRT6 is specifically required for maintaining efficient TPE in human cells.
Many chromatin modifications are highly dynamic, as evidenced by the reversibility of TPE in yeast 1 . To determine whether the loss of telomeric luciferase silencing in SIRT6-depleted cells is reversible, we transiently transfected cells with SIRT6-directed siRNAs and harvested the cells at various time-points after transfection. Recovery of SIRT6 expression over time was sufficient to re-establish silencing of the telomeric luciferase gene (Fig. 2e) , indicating that SIRT6 dynamically regulates TPE. This reversibility also argues that the observed changes in luciferase expression result directly from epigenetic effects on chromatin silencing, and not from any irreversible gross chromosomal abnormalities that have been observed in cells stably depleted of SIRT6 (ref 16 ). Indeed, neither telomere dysfunction nor telomere sequence loss was elevated during the short time-frame of the transient SIRT6 knockdown in our experiments (Fig. 3) , indicating that SIRT6 influences telomeric gene silencing via a mechanism that is independent of such abnormalities.
Maintenance of TPE heterochromatic marks requires SIRT6
To examine the underlying chromatin changes involved in TPE in human cells, we used chromatin immunoprecipitation (ChIP) to measure the occupancy of total histone H3, histone H3 acetylated at lysine 9 (H3K9Ac, a marker of transcriptionally active chromatin), and histone H3 tri-methylated at lysine 9 (H3K9me3, a marker of constitutive heterochromatin) at several loci within the telomeric luciferase gene (Fig. 4a) . As shown in Figure 4b , telomere elongation (following telomerase overexpression, see Fig. 1b ) led to an increase in the density of total histone H3 near telomeres, suggesting that the silencing effect exerted by long telomeres is due to the formation of a closed telomeric chromatin structure. Consistent with this model, hTERT overexpression led to a marked decrease in H3K9Ac and a significant increase in H3K9me3 at these loci (Fig. 4c) . Together, these data demonstrate a profound effect of telomere length on telomere-proximal chromatin structure. Notably, a recent report suggests that, in contrast to the well characterized heterochromatic features of long murine telomeres 29 , the shorter telomeres of primary human cells may not be particularly enriched in marks of heterochromatin 30 . Our observation that long telomeres are associated with a more closed chromatin structure may help explain these differences.
We next asked whether the reactivation of telomeric luciferase expression resulting from SIRT6 depletion is associated with aberrant loss of heterochromatic marks. Indeed, ChIP assays revealed an increase in the active H3K9Ac mark and loss of the heterochromatic H3K9me3 mark at the telomeric luciferase gene in response to RNAi-mediated SIRT6 depletion (Fig. 4d) . Thus, SIRT6 is important for generating a proper telomeric chromatin structure that is required for silencing nearby genes.
Silencing of a natural telomere-proximal gene requires SIRT6
To date, most studies examining regulators of TPE in yeast and human cells have used integrated reporter genes rather than natural telomere-proximal genes. Thus, little is known about how telomeric silencing regulates endogenous gene expression in human cells. A previously reported screen identified one telomere-proximal human gene-interferonstimulated gene 15 (ISG15), located ~1 megabase from the telomere-as being regulated by telomere length in primary and cancer cell lines with natural and manipulated telomere lengths 31 . Consistent with this finding, we observed that in our HeLa cell system, telomere lengthening (via expression of ectopic hTERT, see Fig. 1b ) led to a reduction in ISG15 mRNA levels (Fig. 5a ).
To determine whether SIRT6 is required for TPE-mediated silencing of ISG15, we assessed ISG15 expression in cells depleted of SIRT6. Strikingly, transient siRNA-mediated depletion of SIRT6 led to an increase in ISG15 expression (Fig. 5b) , mirroring the results observed with the telomeric luciferase reporter (see Fig. 2a-b) . This result identifies SIRT6 as the first chromatin regulatory protein required for efficient silencing of an endogenous telomere-proximal gene.
Discussion
Here, we have reported a novel role for SIRT6 in regulating the silencing of genes near telomeres and maintaining the heterochromatic features of telomeric chromatin in human cells. We demonstrate that RNAi-mediated depletion of SIRT6 leads to de-repression of a telomeric transgene, and that recovery of SIRT6 expression is sufficient to re-establish silencing of this transgene. Mechanistically, we find that depletion of SIRT6 disrupts the closed chromatin environment near telomeres. Importantly, we show that SIRT6 is required for repression of an endogenous telomere-proximal gene, suggesting a key role for SIRT6 in maintaining a silencing-competent chromatin structure at natural telomeres. These findings provide the first demonstration of a role for SIRT6 in maintaining transcriptionally silent chromatin domains and identify SIRT6 as the first histone-modifying enzyme that regulates telomere position effect in human cells, thus establishing a new link between SIRT6 and an important aging-associated molecular phenomenon.
Sir2-mediated deacetylation of sub-telomeric histones is important in regulating aging in S. cerevisiae 6 , and localized changes in telomeric chromatin in late-passage human cells have been linked to cellular senescence 30 . Additionally, telomere shortening has been shown to correlate with degenerative pathologies and shortened health span in mammals 32 , and aberrant expression of silent chromatin has been linked to aging and cancer 33, 34 . Because telomeres shorten with each cell division in most somatic human cells, it is possible that telomere erosion-and consequent de-repression of telomere-proximal genes-may in part account for aging-related changes in gene expression 10, 35 . In addition, loss of silencing factors from shortening telomeres might lead to a relocalization of these factors from telomeres to other genomic loci, triggering aberrant silencing of non-telomeric genes 36 . By linking SIRT6 to chromatin silencing at telomeres, our findings highlight an evolutionarily conserved role for sirtuin proteins in the silencing of telomere-proximal genes and suggest a role for SIRT6 in modulating aging-associated changes in chromatin structure and gene expression.
Methods
Cell culture and transfection
HeLa cells harboring telomeric and internal luciferase transgenes have been previously described 11 . Cell lines 97 (telomeric) and 111 (internal) were used for all experiments except those in Figure 2b , which were performed with cell lines 73 (telomeric) and 115 (internal). siRNA transfections were performed using Dharmafect reagent 1 (Dharmacon), according to the manufacturer's instructions, and cells were harvested for luciferase assays and western blots ~72 hours post-transfection unless otherwise indicated. siRNA target sequences are as follows: si SIRT6 #1: AAGAATGTGCCAAGTGTAAGA; si SIRT6 #2: CCGGCTCTGCACCGTGGCTAA; si SIRT1: GATTTAGACGTGTCCGAAT.
Luciferase assays
Luciferase assays were performed using the Luciferase Assay Kit (Promega), using 10 ug of lysate and according to the manufacturer's instructions. Each graph represents three biological replicates.
Antibodies
The antibodies used were as follows: anti-SIRT6 (ref 37 , 0.4 μg/ml), anti-SIRT1 (Santa Cruz, 0.1μg/ml), anti-β-tubulin (Millipore, 0.2 μg/ml), anti-H3K9Ac (Sigma, 1.2 μg per ChIP), anti-H3K9me3 (Abcam, 1.2 μg per ChIP), anti-H3 (Abcam, 1.2 μg per ChIP), anti-TRF2 (Imgenex, 5μg/ml), anti-γ-H2AX (Cell Signaling, 1:400).
Chromatin immunoprecipitation and quantitative real-time PCR
For chromatin immunoprecipitation (ChIP) 16 
Terminal Restriction Fragment (TRF) assay
For telomere length determination, genomic DNA was purified using the Qiagen DNeasy Blood and Tissue Kit, according to the manufacturer's instructions. 2.5 ug of RsaI/HinfI-digested genomic DNA was separated on a 0.7% agarose TAE gel, transferred to Hybond N + (GE Healthcare), and detected using a DIG-labeled telomere probe, using the TeloTAGGG telomere length assay kit (Roche).
Immunofluorescence
For detection of telomere dysfunction-induced foci (TIFs) ~72 hours after siRNA transfection, cells seeded on coverslips were permeabilized with Triton X-100 buffer (0.5% Triton X-100, 20 mM Hepes-KOH pH 7.9, 50 mM NaCl, 3 mM MgCl 2 , 300 mM sucrose) for 5-10 minutes at 4°C to remove soluble nucleoplasmic proteins. After permeabilization cells were fixed in 3% paraformaldehyde/2% sucrose in PBS for 15 minutes at room temperature, re-permeabilized in Triton X-100 buffer, and blocked in PBS + 1% bovine serum albumin. TIFs were detected using antibodies against TRF2 (Imgenex clone 4A794, 5 μg/ml) and γ-H2AX (Cell Signaling rabbit monoclonal clone 20E3, 1:400) and AlexaFluors 488 and 555, respectively (Invitrogen). Coverslips were mounted using ProLong Gold Antifade reagent with DAPI (Invitrogen) and imaged using a Leica DM5000 B microscope, QImaging Retiga EXi Fast 1394 camera, and QCapture Pro imaging software.
Telomere FISH
72 hours after siRNA transfection, metaphase spreads were prepared by treating cells with 100 ng/ml Karyomax colcemid (Invitrogen) for 2.5 hours, swelling in 75 mM KCl, and fixing in 3:1 methanol:acetic acid. Telomere FISH was performed 16 using the Telomere PNA FISH Kit/Cy3 (Dako) according to the manufacturer's instructions. Slides were mounted using ProLong Gold Antifade reagent with DAPI (Invitrogen) and imaged as described above.
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